Over the last 12 months, six Eikon Therapeutics, Inc. the people running the company picked up shares on the open market, about $52.2 million in total, and none of them sold.
Biggest single buyer: Column Group Opportunity III, LP, 10% Owner, with roughly $25.9 million.
On the institutional side, 77 funds reported holding EIKN at the end of Q2 2026, and more funds bought than sold. Quarter by quarter: Last full quarter: net buying by insiders. Insiders bought in 2 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Kutzkey Tim | 10% Owner | Buy | 89,200 | $11.56 | $1.0M | SEC |
| Feb 9, 2026 | Column Group Opportunity III, LP | 10% Owner | Buy | 630,881 | $18.00 | $11.4M | SEC |
| Feb 9, 2026 | Column Group Opportunity III, LP | 10% Owner | Buy | 49,556 | $18.00 | $892K | SEC |
| Feb 9, 2026 | Column Group Opportunity III, LP | 10% Owner | Buy | 1,437,323 | $18.00 | $25.9M | SEC |
| Feb 6, 2026 | Foresite Capital Opportunity Management V, LLC | 10% Owner | Buy | 55,555 | $18.00 | $1000K | SEC |
| Feb 6, 2026 | FRAZIER KENNETH C | Director | Buy | 111,111 | $18.00 | $2.0M | SEC |
| Feb 6, 2026 | Wolfe Josh | Director | Buy | 138,888 | $18.00 | $2.5M | SEC |
| Feb 6, 2026 | Wolfe Josh | Director | Buy | 138,888 | $18.00 | $2.5M | SEC |
| Feb 6, 2026 | Lux Ventures V, L.P. | Director | Buy | 138,888 | $18.00 | $2.5M | SEC |
| Feb 6, 2026 | Lux Ventures V, L.P. | Director | Buy | 138,888 | $18.00 | $2.5M | SEC |
In the last 12 months Eikon Therapeutics, Inc. insiders made open-market purchases worth about $52.2 million and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in EIKN was filed on 2026-09-08.
77 investment managers reported holding EIKN in SEC Form 13F filings for Q2 2026.
No congressional trades in EIKN were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).